Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - methotrexate injection is an anti-metabolite medicine and immunosuppressant. it is used in large doses to treat certain types of cancer such as breast cancer, lung cancer, head and neck cancer, bladder cancer, villous disease (chorionic cancer, estructive molar condition, reward status). in smaller doses it can be used to treat severe psoriasis, when it has not responded to other treatments. it is also used in the treatment of few other non-neoplastic diseases like rheumatoid arthritis and graft versus host disease in bone marrow transplants. extensive treatment of cancer conditions such as: acute leukemia, non-hodgkin's lymphoma, sarcoma (soft sarcoma, osteosarcoma)

Canada - English - Health Canada

pharmascience inc - methotrexate (methotrexate disodium) - tablet - 2.5mg - methotrexate (methotrexate disodium) 2.5mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - united kingdom: methotrexate injection is an anti-metabolite medicine and immunosuppressant. it is used in large doses to treat certain types of cancer such as breast cancer. in smaller doses it can be used to treat severe psoriasis, when it has not responded to other treatments. ireland: methotrexate is used to treat cancer, such as: lymphatic leukemia (disease of the blood or bone marrow), breast cancer, bone cancer, head and neck cancer, gynaecologic cancer (choriocarcinoma, trophoblastic disease ? tumor development directly associated with pregnancy), and non-hodgkin?s lymphoma. methotrexate can also be used to treat severe psoriasis, when it has not responded to other treatments.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 25 mg/ml;   - solution for injection - 25 mg/ml - active: methotrexate 25 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

Malta - English - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Malta - English - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Malta - English - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 1000 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.